Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
RSLV-132 by Resolve Therapeutics for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
RSLV-132 is under clinical development by Resolve Therapeutics and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC...
RSLV-132 by Resolve Therapeutics for Primary Sjogren's Syndrome: Likelihood of Approval
RSLV-132 is under clinical development by Resolve Therapeutics and currently in Phase II for Primary Sjogren's Syndrome. According to GlobalData,...
RSLV-132 by Resolve Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval
RSLV-132 is under clinical development by Resolve Therapeutics and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...